Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03614689

Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire

Sponsor: Geneplus-Beijing Co. Ltd.

View on ClinicalTrials.gov

Summary

To analyze the proportion of hereditary tumors in ovarian cancer patients in China, as well as the spectrum of variations; the ctDNA characteristics in patients with ovarian cancer; the correlation between the clonal status of mutations and therapy response; whether ctDNA detection can be used to predict the risk of ovarian cancer recurrence; and the characteristics of immune repertoire before and after treatment in patients with ovarian cancer.

Key Details

Gender

FEMALE

Age Range

18 Years - 80 Years

Study Type

OBSERVATIONAL

Enrollment

104

Start Date

2017-11-25

Completion Date

2024-12

Last Updated

2024-07-18

Healthy Volunteers

No

Conditions

Locations (6)

Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University

Changsha, Hunan, China

The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China

Sichuan Cancer Hospital

Chengdu, Sichuan, China

Affiliated Cancer Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, China

Peking Union Medical College Hospital

Beijing, China

Peking University International Hospital

Beijing, China